International Apparel Expo 2010

IIGF 2010 - 44th India International Garment Fair Hong Kong Fashion Week for Fall/Winter Aura Herbal Textiles Limited Brand Story - GAP
   Home > News [P] - [For Subscribers]
Textile Apparel Fashion  Technology General  Corporate Associations

Announcement | Association/Org | Company | Education/Training | HR | Policy | Environment/Pollution | Fair/Events | Import/Export | Market Trends | Results/Reports | Retail/Chain Stores | Leather/Footwear | Dow Jones Indexes

Find Buyer/Seller of:
Find Used Machinery Buyer/Seller:

General Articles
Advanced Analytical Methods of Training
Determine Your Website Strategy for Online Success
Consumer Trends for 2010, and beyond
Factoring-A Step Ahead Towards Modernisation
Aligning Marketing with Business Strategy
International Year of Natural Fibres 2009
TAIEx 2010 - Conference on Global Textiles & Exhibition of Textile Machinery & Allied sector
Nonwovensupplier - Flip through the ready reckoner of global suppliers
Australia : ACCC accepts divestitures by Johnson & Johnson
January 2, 2007

The Australian Competition and Consumer Commission has accepted a divestiture proposal offered by Johnson & Johnson and will not oppose J&J's proposed acquisition of the consumer healthcare business of Pfizer Inc.

"J&J and Pfizer have each provided court enforceable undertakings to allay the ACCC's competition concerns about the impact of J&J's proposed acquisition in the worm treatments, anti-diarrhoeal and nicotine replacement therapy product categories", said ACCC Chairman, Mr Graeme Samuel.

"J&J's undertaking requires J&J to divest its Vermox brand in the worm treatments product category, and Pfizer's anti-diarrhoeals brands Lomotil and Lofenoxal", Mr Samuel said.

"In addition, the undertakings provided by J&J and Pfizer provide that, if required, J&J and/or Pfizer will assist the proposed purchaser/s of these divested brands to secure a source of supply of the products corresponding with these brands on competitive terms for a period of two to three years after their sale.

"J&J's undertaking also requires it to divest part or all of its global nicotine replacement therapy business including, if required, the manufacturing assets of this business", Mr Samuel said. To achieve this divestiture, J&J has undertaken to comply with its divestiture commitments to the European Commission, and to obtain ACCC approval for any proposed purchaser of the business.

"The ACCC conducted market inquiries about the impact of the proposed acquisition and J&J's divestiture proposal on competition in the supply of worm treatments, anti-diarrhoeals and nicotine replacement therapy products in Australia. It has decided that, subject to the divestitures, the proposed acquisition will not lead to a substantial lessening of competition in any of the relevant product categories".

The J&J and Pfizer undertakings will appear on the ACCC's website public register shortly. A Public Competition Assessment will be published in due course.
 
Australian Competition and Consumer Commission

More General News - Australia
More General Association Org News - Australia

  Email This Story |  Letter To Editor |  Sign Up for News Letter |  Print Story
Bookmark this news to your favorite bookmarking sites   Bookmark and Share

Disclaimer | About Us | Enquiry | Sitemap | Our Services | Feedback / Comments | Internet Rank
Copyright © 2009.
All rights reserved by
Sanblue Enterprises Pvt. Ltd.
For best view:
Use Internet Explorer 5.0+,
Screen resolution 1024 x 768
ICICI Payment Gateway
Secure Merchant
ISO 9001 certified